Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLyell Immunopharma, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q2 2024 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q3 2024 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q4 2024 | 2 | -$0.21 | -$0.17 | -$0.18 |
| Q1 2025 | 2 | -$0.19 | -$0.18 | -$0.19 |
| Q2 2025 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q3 2025 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q4 2025 | 1 | -$0.23 | -$0.23 | -$0.23 |
Lyell Immunopharma, Inc. Earnings Date And Information
Lyell Immunopharma, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.17 earnings per share for the quarter, topping analysts' consensus estimates of $-0.2 by $0.03. The company had revenue of 34,000 for the quarter and had revenue of 130,000 for the year. Lyell Immunopharma, Inc. has generated $-1 earnings per share over the last year ($-0.93 diluted earnings per share) and currently has a price-to-earnings ratio of -0.82. Lyell Immunopharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Lyell Immunopharma, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.20 | -$0.17 | 0.03 | $34,000 | $34,000 |
| 08/07/2024 | Q2 2024 | -$0.20 | -$0.18 | 0.02 | $3,250 | $13,000 |
| 05/06/2024 | Q1 2024 | -$0.20 | -$0.24 | -0.04 | $3,000 | |
| 12/29/2023 | Q4 2023 | -$0.21 | $13,000 | |||
| 11/07/2023 | Q3 2023 | -$0.27 | -$0.20 | 0.07 | $6,250 | $25,000 |
| 08/08/2023 | Q2 2023 | -$0.30 | -$0.26 | 0.04 | $18,000 | $27,000 |
| 05/04/2023 | Q1 2023 | -$0.28 | -$0.53 | -0.25 | $65,000 | |
| 02/28/2023 | Q4 2022 | -$0.31 | $0.01 | 0.32 | $48,386 | |
| 11/08/2022 | Q3 2022 | -$0.34 | -$0.30 | 0.04 | $1.80 M | $3,000 |
| 08/04/2022 | Q2 2022 | -$0.31 | -$0.15 | 0.16 | $17.87 M | $35.74 M |
| 05/10/2022 | Q1 2022 | -$0.28 | $553,000 | |||
| 03/29/2022 | Q4 2021 | -$0.29 | -$0.35 | -0.06 | $2.82 M | |
| 11/12/2021 | Q3 2021 | -$0.27 | -$0.20 | 0.07 | $2.88 M | $2.76 M |
| 08/12/2021 | Q2 2021 | -$0.36 | -$1.47 | -1.11 | $2.31 M | $2.63 M |
| 03/30/2021 | Q1 2021 | -$0.23 | $2.45 M | |||
| 12/31/2020 | Q4 2020 | -$0.18 | $2.31 M | |||
| 09/29/2020 | Q3 2020 | -$0.17 | $1.07 M | |||
| 06/29/2020 | Q2 2020 | -$0.48 | $3.12 M | |||
| 03/30/2020 | Q1 2020 | -$0.14 | $1.26 M |
Lyell Immunopharma, Inc. Earnings: FAQ's
When is Lyell Immunopharma, Inc.'s earnings date?
Lyell Immunopharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
Did Lyell Immunopharma, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Lyell Immunopharma, Inc. (:LYEL) reported $-0.17 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.2 by $0.03.
How can I listen to Lyell Immunopharma, Inc.'s earnings conference
call?
The conference call for Lyell Immunopharma, Inc.'s latest earnings report can be listened to online.
How can I read Lyell Immunopharma, Inc.'s conference call transcript?
The conference call transcript for Lyell Immunopharma, Inc.'s latest earnings report can be read online.
How much revenue does Lyell Immunopharma, Inc. generate each year?
Lyell Immunopharma, Inc. (:LYEL) has a recorded annual revenue of $130,000.
How much profit does Lyell Immunopharma, Inc. generate each year?
Lyell Immunopharma, Inc. (:LYEL) has a recorded net income of $130,000. Lyell Immunopharma, Inc. has generated $-0.93 earnings per share over the last four quarters.
What is Lyell Immunopharma, Inc.'s price-to-earnings ratio?
Lyell Immunopharma, Inc. (:LYEL) has a price-to-earnings ratio of -0.82 and price/earnings-to-growth ratio is -0.23.